Leukemia cells hide behind a sugar coat, making them invisible to your immune system
Cancer cells are skilled escape artists. But leukemia cells have a particularly elegant trick: they coat themselves in sugar molecules that actively send a stop signal to the immune system.
The immune system identifies foreign or dangerous cells through a set of surface receptors — molecular sensors constantly scanning whatever they encounter. One group of these sensors, called Siglec receptors, are activated by sialic acid, a specific type of sugar molecule that normally decorates the outer surface of healthy body cells. The signal they transmit is: ‘this is self, leave it alone.’ An elegant self-regulatory system in healthy tissue.
Leukemia cells exploit that system. They overproduce sialic acid on their surface, effectively installing a counterfeit passport that makes them appear normal. The result: T-cells and other immune cells that approach the leukemia cells receive an inhibitory signal through the Siglec receptors and stand down. The tumor grows undisturbed, protected by a biochemical shield that the immune system itself built and that cancer cells have cleverly hijacked.
CD43: the gatekeeper of the shield
The new study, published in Science, identifies a specific molecule as the central hub of that shield: CD43, a protein found on the surface of white blood cells that is heavily sialylated — blanketed in sialic acid. The researchers demonstrated that CD43 on leukemia cells functions as an active brake on the immune response: it binds to Siglec receptors on attacking T-cells and effectively shuts them down. When the sialylation of CD43 was chemically or genetically blocked, the immune response recovered, and leukemia cells were targeted and killed far more effectively.
This mechanism may explain why certain forms of leukemia respond poorly to immunotherapies that work well in other cancers. Checkpoint inhibitors, the immunotherapy that revolutionized melanoma and lung cancer treatment, target different inhibitory pathways. The glyco-immune shield operating through CD43 and Siglec is a parallel system, largely overlooked until now.
A new target for treatment
The researchers propose several therapeutic strategies. One approach involves blocking the interaction between sialylated CD43 and Siglec receptors using antibodies. Another uses enzymes called sialidases that clip the sialic acid off the tumor surface, dismantling the shield and leaving cancer cells exposed to immune attack. In mouse models, both approaches worked: tumors shrank, survival improved.
The distance between a mouse model and an effective human treatment is vast, littered with failed clinical trials. But the conceptual advance this study represents is significant: it demonstrates that the sugar coat on cancer cells is not a passive feature but an active and targeted immune evasion mechanism. Active mechanisms are, in principle, switchable. Whether that holds true in the clinic is a question the coming years will need to answer.